DIASORIN: LAUNCH OF THE LIAISON® QUICK DETECT COVID AG ASSAY, AN ANTIGEN TEST TO DETECT COVID-19 INFECTION AVAILABLE ON THE POINT-OF-CARE LIAISON® IQ PLATFORM IN MARKETS ACCEPTING CE MARK

THE LIAISON® QUICK DETECT COVID AG ASSAY:
- ALLOWS THE DETECTION OF COVID-19 INFECTION THROUGH NASAL AND NASOPHARYNGEAL SWABS
- DELIVERS RESULTS WITH 95.7% SENSITIVITY AND 96.3% SPECIFICITY COMPARED TO ULTRA-SENSITIVE PCR ON NASAL AND NASOPHARYNGEAL SWABS AND IS BASED ON LATERAL-FLOW TECHNOLOGY
- WILL BE RUN ON THE LIAISON® IQ IMMUNODIAGNOSTIC POINT-OF-CARE (POC) PLATFORM
- IS AVAILABLE IN MARKETS ACCEPTING THE CE MARK

Saluggia - May 25, 2021 - Diasorin (FTSE MIB: DIA) launched today the new LIAISON® Quick Detect COVID Ag Assay, a new Point-of-Care (POC) test available in markets accepting the CE Mark, for the detection of SARS-CoV-2 antigen through nasal and nasopharyngeal swabs using lateral-flow technology.

The LIAISON® Quick Detect COVID Ag Assay is available for use on the LIAISON® IQ, the recently launched immunodiagnostic POC platform, which has been available in markets accepting the CE Mark since April 20, 2021. In clinical studies, LIAISON® Quick Detect COVID Ag Assay showed a 95.7% sensitivity and a 96.3% specificity compared to results obtained from ultra-sensitive PCR on nasal and nasopharyngeal swabs with Ct counts of 30 or below.

The LIAISON® Quick Detect COVID Ag Assay is intended as a near-patient testing solution that detects COVID-19 infection. The test was developed by Lumos Diagnostics, diagnostic specialists with experience in the customized development and manufacturing of rapid, high-quality and cutting-edge POC diagnostic test solutions, and is CE marked for use on the LIAISON® IQ platform, in the context of the collaboration between Diasorin and Lumos announced on April 6, 2021.

Diasorin recently entered the immunodiagnostic POC market starting with a dedicated program in Italy, targeting pharmacies through agreements with distributors to foster widespread placements of the new POC platform and the first two COVID-19 assays now available for use with it (LIAISON® Quick Detect COVID Ag Assay and LIAISON® Quick Detect COVID TrimericS Ab).

“With the launch of this solution we are adding to our COVID-19 test offering for the LIAISON® IQ a new important diagnostic tool,” commented Carlo Rosa, CEO of Diasorin Group. “We acknowledged the importance, in this phase, of providing near-patient solutions for COVID-19 that can detect not only the presence of a specific immune response developed post-vaccination or infection, but also active COVID-19 infections with reliable results. We are entering this new market with a strategy dedicated initially to Italy and to the current pandemic emergency, but this is just a first step in our Point-of-Care strategy for the launch of several lab-quality solutions.”

For additional information, please contact:

Riccardo Fava
Corporate Vice President Communication & Investor Relations
Tel: +39.0161.487988
riccardo.fava@diasorin.it

Emanuela Salvini
Investor Relator
Tel: +39.0161.487567
emanuela.salvini@diasorin.it

Diasorin
Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, Diasorin is a global leader in the In Vitro Diagnostic (IVD) field, with 26 companies, 4 branches, 5 manufacturing facilities and 5 research and development centers.

For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The extensive diagnostic testing offer, made available through continuous investments in research, positions Diasorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”.

More info at www.diasoringroup.com